Content
Week In Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Article By:
ChinaBio® Today
Read
Saturday, January 20, 2024 2:40 PM EDT
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line.
MicroMarvel: Mereo BioPharma - Analysts Favorite
Article By:
Jim Van Meerten
Read
Tuesday, January 16, 2024 8:59 AM EDT
Mereo BioPharma develops therapeutics for oncology and rare diseases, with strong buy recommendations and price targets between $4 and $5.
In this article: MREO
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Article By:
ChinaBio® Today
Read
Saturday, January 13, 2024 1:20 PM EDT
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
Chart Of The Day: IDEAYA Biosciences - Oncology Biomedicine
Article By:
Jim Van Meerten
Read
Thursday, January 11, 2024 11:00 AM EDT
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
In this article: IDYA
Immunome - Oncology Is Hot
Article By:
Jim Van Meerten
Read
Wednesday, January 10, 2024 5:44 PM EDT
Immunome, an oncology biomedical company, has gained 27.48% since a buy signal on December 22.
In this article: IMNM
Chart Of The Day: Elanco Animal Health- Big Money In Animal Pharma
Article By:
Jim Van Meerten
Read
Wednesday, January 10, 2024 8:49 AM EDT
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals
In this article: ELAN
MicroMarvet - Fulcrum Therapeutics - Confusing Projections And Recommendation
Article By:
Jim Van Meerten
Read
Tuesday, January 9, 2024 9:08 AM EDT
Revenue is estimated to be down 63.40% this year and down another 19.80% next year. Earnings are projected to increase 32.80% this year but be down 9.80% next year.
In this article: FULC
Chart Of The Day: Innoviva - Individual Investor Favorite
Article By:
Jim Van Meerten
Read
Monday, January 8, 2024 8:38 PM EDT
100% technical buy signals
14 new highs and up 12.87% in the last month
36.40+ Weighted Alpha
In this article: INVA
The Canadian Cannabis Report- Monday, Jan. 8
Article By:
James Coleman
Read
Monday, January 8, 2024 12:17 PM EDT
The past, present and future of the Canadian cannabis sector based on the MCCCI, which is a proprietary index of 14 stocks.
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Article By:
Zacks Investment Research
Read
Sunday, January 7, 2024 9:00 AM EDT
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech stocks that will likely perform well in 2024.
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Article By:
ChinaBio® Today
Read
Sunday, January 7, 2024 7:20 AM EDT
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China) for AVZO-021 to Avenzo Therapeutics.
